(Q34635834)

3 August 2017

1 reference

title

The evolving role of systemic therapy in high risk prostate cancer: strategies for cure in the 21st century (English)

1 reference

3 August 2017

1 reference

Ulka Vaishampayan

1

1 reference

3 August 2017

Maha Hussain

series ordinal

2

1 reference

3 August 2017

publication date

1 May 2002

1 reference

Critical Reviews in Oncology Hematology

3 August 2017

published in

1 reference

3 August 2017

volume

42

1 reference

3 August 2017

issue

2

1 reference

3 August 2017

page(s)

179-188

1 reference

3 August 2017

cites work

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Prostate cancer histologic trends in the metropolitan Detroit area, 1982 to 1996.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Total prostatectomy for clinically localized prostatic cancer: long-term results

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Control of prostate cancer with radiotherapy: long-term results.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

The Pathological Features and Prognosis of Prostate Cancer Detectable With Current Diagnostic Tests

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Cancer statistics, 1993

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Effect of age and race on the survival of men with prostate cancer in the Metropolitan Detroit tricounty area, 1973 to 1987

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Treatment options for localized prostate cancer based on pretreatment serum prostate specific antigen levels

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Correlation of pathologic findings with progression after radical retropubic prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Prognostic significance of positive surgical margins in radical prostatectomy specimens

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

The incidence and significance of seminal vesicle invasion in patients with adenocarcinoma of the prostate.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Pathogenesis and biological significance of seminal vesicle invasion in prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Ten-year outcomes for pathologic node-positive patients treated in RTOG 75-06

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for adenocarcinoma of prostate with regional lymph node involvement

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Calculated prostate carcinoma volume: The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4-20 nanograms per milliliter

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Comparing clinical staging plus transrectal ultrasound with surgical-pathologic staging of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Endorectal coil magnetic resonance imaging identifies locally advanced prostate cancer in select patients with clinically localized disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

The prognostic value of DNA ploidy combined with histologic substaging for incidental carcinoma of the prostate gland

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Detection of prostatic cancer by solid-phase radioimmunoassay of serum prostatic acid phosphatase

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Prostate specific antigen and prostatic acid phosphatase immunoreactivity as prognostic indicators of advanced prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Elevated Plasma Chromogranin-A Concentrations in Prostatic Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Serum metalloproteinases and their inhibitors: markers for malignant potential

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Radical prostatectomy for pathologic stage C prostate cancer: influence of pathologic variables and adjuvant treatment on disease outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Influence of DNA ploidy and adjuvant treatment on progression and survival in patients with pathologic stage T3 (PT3) prostate cancer after radical retropubic prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Adjuvant hormone therapy after radical prostatectomy: indications and results.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Hormonal treatment before radical prostatectomy: a 3-year followup

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

First International Conference on Neoadjuvant Hormonal Therapy of Prostate Cancer: overview consensus statement

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Adjuvant therapy for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Adjuvant mitozantrone chemotherapy in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Estramustine: a novel radiation enhancer in human carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Effect of estramustine, etoposide, and taxol on prostate cancer cell growth in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

Neoadjuvant estramustine and etoposide followed by concurrent estramustine and definitive radiotherapy for locally advanced prostate cancer: feasibility and preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900187-1

7 January 2021

10.1016/S1040-8428(01)00187-1

Identifiers

DOI

1 reference

3 August 2017

1 reference